WO2002055014A2 - Therapeutic chroman compounds - Google Patents

Therapeutic chroman compounds Download PDF

Info

Publication number
WO2002055014A2
WO2002055014A2 PCT/SE2002/000070 SE0200070W WO02055014A2 WO 2002055014 A2 WO2002055014 A2 WO 2002055014A2 SE 0200070 W SE0200070 W SE 0200070W WO 02055014 A2 WO02055014 A2 WO 02055014A2
Authority
WO
WIPO (PCT)
Prior art keywords
sep
optionally substituted
piperazin
methyl
oxo
Prior art date
Application number
PCT/SE2002/000070
Other languages
English (en)
French (fr)
Other versions
WO2002055014A3 (en
Inventor
Marc Chapdelaine
Timothy Davenport
Markus Haeberlein
Carey Horchler
John Mccauley
Edward Pierson
Daniel Sohn
Original Assignee
Astrazeneca Ab
Marc Chapdelaine
Timothy Davenport
Markus Haeberlein
Carey Horchler
John Mccauley
Edward Pierson
Daniel Sohn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0103646A external-priority patent/SE0103646D0/xx
Priority to US10/466,565 priority Critical patent/US20040110745A1/en
Priority to CNB02806562XA priority patent/CN100384833C/zh
Priority to EP02715919A priority patent/EP1353915A2/en
Priority to IL15660102A priority patent/IL156601A0/xx
Priority to BR0206514-2A priority patent/BR0206514A/pt
Priority to AU2002225551A priority patent/AU2002225551B8/en
Priority to NZ526699A priority patent/NZ526699A/en
Priority to KR10-2003-7009435A priority patent/KR20030070917A/ko
Priority to JP2002555751A priority patent/JP4280068B2/ja
Priority to MXPA03006261A priority patent/MXPA03006261A/es
Application filed by Astrazeneca Ab, Marc Chapdelaine, Timothy Davenport, Markus Haeberlein, Carey Horchler, John Mccauley, Edward Pierson, Daniel Sohn filed Critical Astrazeneca Ab
Priority to CA002434015A priority patent/CA2434015A1/en
Publication of WO2002055014A2 publication Critical patent/WO2002055014A2/en
Publication of WO2002055014A3 publication Critical patent/WO2002055014A3/en
Priority to IL156601A priority patent/IL156601A/en
Priority to NO20033205A priority patent/NO20033205L/no
Priority to IL183183A priority patent/IL183183A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
PCT/SE2002/000070 2001-01-16 2002-01-15 Therapeutic chroman compounds WO2002055014A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CA002434015A CA2434015A1 (en) 2001-01-16 2002-01-15 Therapeutic chroman compounds
MXPA03006261A MXPA03006261A (es) 2001-01-16 2002-01-15 Compuestos terapeuticos de cromano.
JP2002555751A JP4280068B2 (ja) 2001-01-16 2002-01-15 治療用クロマン化合物
IL15660102A IL156601A0 (en) 2001-01-16 2002-01-15 Therapeutic chroman compounds
CNB02806562XA CN100384833C (zh) 2001-01-16 2002-01-15 治疗用苯并二氢吡喃化合物
AU2002225551A AU2002225551B8 (en) 2001-01-16 2002-01-15 Therapeutic chroman compounds
NZ526699A NZ526699A (en) 2001-01-16 2002-01-15 8-amino derivatives and their use in treating migraine
US10/466,565 US20040110745A1 (en) 2001-11-01 2002-01-15 Therapeutic chroman compounds
EP02715919A EP1353915A2 (en) 2001-01-16 2002-01-15 Therapeutic chroman compounds
BR0206514-2A BR0206514A (pt) 2001-01-16 2002-01-15 Composto, método de tratamento de um ser humano ou animal que sofre de enxaqueca, uso do composto, composição farmacêutica, e, processo para preparar um composto
KR10-2003-7009435A KR20030070917A (ko) 2001-01-16 2002-01-15 치료용 크로만 화합물
IL156601A IL156601A (en) 2001-01-16 2003-06-23 Novel compounds and pharmaceutical preparations containing them
NO20033205A NO20033205L (no) 2001-01-16 2003-07-15 Terapeutiske kromanforbindelser
IL183183A IL183183A0 (en) 2001-01-16 2007-05-14 Therapeutic chroman compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26210801P 2001-01-16 2001-01-16
US60/262,108 2001-01-16
SE0103646-6 2001-11-01
SE0103646A SE0103646D0 (sv) 2001-11-01 2001-11-01 Therapeutic chroman compounds

Publications (2)

Publication Number Publication Date
WO2002055014A2 true WO2002055014A2 (en) 2002-07-18
WO2002055014A3 WO2002055014A3 (en) 2002-11-14

Family

ID=26655581

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2002/000070 WO2002055014A2 (en) 2001-01-16 2002-01-15 Therapeutic chroman compounds

Country Status (15)

Country Link
EP (1) EP1353915A2 (ja)
JP (1) JP4280068B2 (ja)
KR (1) KR20030070917A (ja)
CN (1) CN100384833C (ja)
AR (1) AR036327A1 (ja)
AU (1) AU2002225551B8 (ja)
BR (1) BR0206514A (ja)
CA (1) CA2434015A1 (ja)
IL (3) IL156601A0 (ja)
MX (1) MXPA03006261A (ja)
MY (1) MY138263A (ja)
NO (1) NO20033205L (ja)
NZ (1) NZ526699A (ja)
SA (1) SA02220709B1 (ja)
WO (1) WO2002055014A2 (ja)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1451158A1 (en) * 2001-11-01 2004-09-01 AstraZeneca AB Therapeutic quinoline compounds with 5-ht-antagonistic properties
WO2007094718A1 (en) * 2006-02-14 2007-08-23 Astrazeneca Ab Radioligands for the 5 -ht1b receptor
WO2007097697A1 (en) * 2006-02-23 2007-08-30 Astrazeneca Ab Therapeutic quinoline compounds that are 5ht1b modulators
JP2007528880A (ja) * 2004-03-12 2007-10-18 ハー・ルンドベック・アクチエゼルスカベット 置換されたモルホリンおよびチオモルホリン誘導体
EP1945624A1 (en) * 2005-11-04 2008-07-23 Astra Zeneca AB Chroman compounds as 5-ht1b antagonists
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US7777036B2 (en) 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
WO2010128345A1 (en) * 2009-05-05 2010-11-11 Szegedi Tudományegyetem Kynurenic acid analogues, pharmaceutical compositions containing same and use of said compounds for the treatment of headache
US7919496B2 (en) 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
US8026360B2 (en) 2004-09-20 2011-09-27 Xenon Pharmaceuticals Inc. Substituted pyridazines as stearoyl-CoA desaturase inhibitors
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US8110687B2 (en) 2005-12-08 2012-02-07 Millennium Pharmaceuticals, Inc. Bicyclic compounds with kinase inhibitory activity
US8541457B2 (en) 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds
US9975886B1 (en) 2017-01-23 2018-05-22 Cadent Therapeutics, Inc. Potassium channel modulators
US10774064B2 (en) 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
US11993586B2 (en) 2019-10-21 2024-05-28 Novartis Ag Crystalline forms of potassium channel modulators

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1275341C (zh) 1996-08-08 2006-09-13 日立化成工业株式会社 生产用于锂二次电池的负极的方法
US7812206B2 (en) 2006-03-21 2010-10-12 Bp Corporation North America Inc. Apparatus and process for the separation of solids and liquids
US8530716B2 (en) 2008-08-14 2013-09-10 Bp Corporation North America Inc. Melt-crystallization separation and purification process
CN104262249A (zh) * 2014-10-20 2015-01-07 云南民族大学 一种喹诺酮化合物的绿色高效制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8515389D0 (en) * 1985-06-18 1985-07-17 Ici Plc Heterocyclic compounds
US5112856A (en) * 1986-08-15 1992-05-12 Hoffmann-La Roche Inc. Therapeutic treatment of intestinal inflammation by administration of 3,4-dihydro-2H-1-benzopyran derivatives
SE8904361D0 (sv) * 1989-12-22 1989-12-22 Astra Ab New chroman and thiochroman derivatives
DE4140542A1 (de) * 1991-12-09 1993-06-17 Bayer Ag Piperdylmethyl substituierte chormanderivate
FR2761358B1 (fr) * 1997-03-27 1999-05-07 Adir Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SE9703378D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
FR2782515B1 (fr) * 1998-08-21 2000-09-22 Adir NOUVEAUX DERIVES DE L'INDANE-1-Ol, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BARNES; SHARP, NEUROPHARMACOLOGY, vol. 38, 1999, pages 1083 - 1152
J. MED. CHEM, vol. 41, 1998, pages 1218 - 1235
J. MED. CHEM, vol. 42, 1999, pages 4981 - 5001
LAZARENO, S., METHODS IN MOLECULAR BIOLOGY, vol. 106, 1999, pages 231 - 245
ROBERTS ET AL., BR. J. PHARMACOL., vol. 117, 1996, pages 384 - 388

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1451158A1 (en) * 2001-11-01 2004-09-01 AstraZeneca AB Therapeutic quinoline compounds with 5-ht-antagonistic properties
US8299075B2 (en) 2004-03-12 2012-10-30 H. Lundbeck A/S Substituted thiomorpholine derivatives
US8012962B2 (en) 2004-03-12 2011-09-06 H. Lundbeck A/S Substituted thiomorpholine derivatives
JP2007528880A (ja) * 2004-03-12 2007-10-18 ハー・ルンドベック・アクチエゼルスカベット 置換されたモルホリンおよびチオモルホリン誘導体
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US7777036B2 (en) 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
US8026360B2 (en) 2004-09-20 2011-09-27 Xenon Pharmaceuticals Inc. Substituted pyridazines as stearoyl-CoA desaturase inhibitors
US7919496B2 (en) 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
US8541457B2 (en) 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
EP1945624A1 (en) * 2005-11-04 2008-07-23 Astra Zeneca AB Chroman compounds as 5-ht1b antagonists
EP1945624A4 (en) * 2005-11-04 2010-06-30 Astrazeneca Ab CHROMIN COMPOUNDS AS 5-HT1B ANTAGONISTS
US8110687B2 (en) 2005-12-08 2012-02-07 Millennium Pharmaceuticals, Inc. Bicyclic compounds with kinase inhibitory activity
WO2007094718A1 (en) * 2006-02-14 2007-08-23 Astrazeneca Ab Radioligands for the 5 -ht1b receptor
WO2007097697A1 (en) * 2006-02-23 2007-08-30 Astrazeneca Ab Therapeutic quinoline compounds that are 5ht1b modulators
WO2010128345A1 (en) * 2009-05-05 2010-11-11 Szegedi Tudományegyetem Kynurenic acid analogues, pharmaceutical compositions containing same and use of said compounds for the treatment of headache
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds
US10774064B2 (en) 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
US9975886B1 (en) 2017-01-23 2018-05-22 Cadent Therapeutics, Inc. Potassium channel modulators
US10351553B2 (en) 2017-01-23 2019-07-16 Cadent Therapeutics, Inc. Potassium channel modulators
US10717728B2 (en) 2017-01-23 2020-07-21 Cadent Therapeutics, Inc. Potassium channel modulators
US11993586B2 (en) 2019-10-21 2024-05-28 Novartis Ag Crystalline forms of potassium channel modulators

Also Published As

Publication number Publication date
AU2002225551B8 (en) 2008-05-29
NO20033205L (no) 2003-09-02
IL156601A (en) 2009-06-15
SA02220709B1 (ar) 2007-01-23
NO20033205D0 (no) 2003-07-15
CN100384833C (zh) 2008-04-30
AU2002225551B2 (en) 2008-04-03
NZ526699A (en) 2005-03-24
MXPA03006261A (es) 2003-09-22
CA2434015A1 (en) 2002-07-18
KR20030070917A (ko) 2003-09-02
JP2004517130A (ja) 2004-06-10
CN1524077A (zh) 2004-08-25
JP4280068B2 (ja) 2009-06-17
AR036327A1 (es) 2004-09-01
BR0206514A (pt) 2004-01-06
WO2002055014A3 (en) 2002-11-14
IL183183A0 (en) 2007-08-19
MY138263A (en) 2009-05-29
IL156601A0 (en) 2004-01-04
EP1353915A2 (en) 2003-10-22

Similar Documents

Publication Publication Date Title
AU2002217742B2 (en) Therapeutic heterocyclic compounds
AU2002217742A1 (en) Therapeutic heterocyclic compounds
US20050085457A1 (en) Therapeutic quinolone compounds with 5-ht-antagonistic properties
AU2002225551B2 (en) Therapeutic chroman compounds
AU2002225551A1 (en) Therapeutic chroman compounds
US20050096312A1 (en) Therapeutic quinolone compounds with 5-ht-antagonistic properties
WO2002055013A2 (en) Therapeutic chromone compounds
US20040110745A1 (en) Therapeutic chroman compounds
AU2002219770A1 (en) Therapeutic chromone compounds
US20040082591A1 (en) Therapeutic heterocyclic compounds
US20060019947A1 (en) Therapeutic chromone compounds
NZ545374A (en) Process for the production of therapeutic heterocyclic compounds
AU2002348559A1 (en) Therapeutic quinolone compounds with 5-HT-antagonistic properties
AU2002348560A1 (en) Therapeutic quinoline compounds with 5-HT-antagonistic properties

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002225551

Country of ref document: AU

Ref document number: 156601

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 526699

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002715919

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2434015

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003/05318

Country of ref document: ZA

Ref document number: 200305318

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/A/2003/006261

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002555751

Country of ref document: JP

Ref document number: 1020037009435

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 10466565

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1020037009435

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 02806562X

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002715919

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 526699

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 526699

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 183183

Country of ref document: IL